Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data.

ABSTRACT:

Purpose

While clinical RCTs have clearly evidenced that the use of androgen receptor pathway inhibitor (ARPI)s for patients with advanced prostate cancer, can significantly delay disease progression, there is insufficient evidence on their safety profiles to warrant their unqualified implementation as the treatment of choice or with which to choose between them. We aim to provide more substantial evidence for adverse event (AE)s of ARPI by analyzing real-world data (RWD) to select optimal ARPI for individual treatment.

Materials and methods

We used data from the Food and Drug Administration Adverse Event Reporting System (FAERS) in the US, between April 30, 2014 and April 30, 2024.

Results

We estimated proportional risk ratio (PRR)s of AEs in the US. We also compared

SUBMITTER: Lee J 

PROVIDER: S-EPMC12551900 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature